Mega Lifesciences（MEGA）株式概要
メガ・ライフサイエンス社（Mega Lifesciences Public Company Limited）は、その子会社とともに、東南アジアおよびサハラ以南のアフリカで、健康食品、医療用医薬品、一般用医薬品、ハーブ製品、ビタミン剤、日用消費財を製造・販売している。 詳細
MEGA Community Fair Values
Create NarrativeSee what 15 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Mega Lifesciences Public Company Limited 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | ฿35.75 |
| 52週高値 | ฿40.00 |
| 52週安値 | ฿24.60 |
| ベータ | 0.32 |
| 1ヶ月の変化 | 2.14% |
| 3ヶ月変化 | 5.93% |
| 1年変化 | 37.50% |
| 3年間の変化 | -8.33% |
| 5年間の変化 | -3.38% |
| IPOからの変化 | 67.84% |
最新ニュース
ナラティブの更新 • Jun 07
MEGA: Stable Assumptions And Margin Outlook Will Drive Future Upside
Analysts have kept their price target for Mega Lifesciences unchanged at THB 41.14, citing only small adjustments to projected revenue growth, profit margins and future P/E assumptions that do not materially alter their overall view of the stock. What's in the News No recent company specific news for Mega Lifesciences has been provided in the available sources.ナラティブの更新 • May 24
MEGA: Higher Margin Outlook And Dividend Decision Will Support Future Upside
Analysts have trimmed their price target for Mega Lifesciences slightly to THB 41.14 from THB 41.17, reflecting updated assumptions that now pair a lower revenue growth outlook of 4.12% with a higher projected profit margin of 16.40% and a modestly lower future P/E of 16.67x. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).ナラティブの更新 • May 06
MEGA: Stable Outlook And Upcoming Dividend Decision Will Drive Further Upside
Analysts have kept their fair value estimate for Mega Lifesciences steady at THB41.17 per share, with only minimal model tweaks related to the discount rate, profit margin outlook and future P/E assumptions. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).
ナラティブの更新 • Apr 21
MEGA: Higher Growth And Lower Margins Will Likely Keep Shares Fairly Valued
Analysts have lifted their price target on Mega Lifesciences from THB 32 to THB 35, citing updated assumptions around higher revenue growth, a slightly lower discount rate and a revised future P/E multiple, partially offset by a more conservative profit margin outlook. What's in the News Board meeting scheduled for Feb 24, 2026, to consider a dividend payment proposal for the year ended Dec 31, 2025 (company filing).Recent updates
ナラティブの更新 • Jun 07
MEGA: Stable Assumptions And Margin Outlook Will Drive Future Upside
Analysts have kept their price target for Mega Lifesciences unchanged at THB 41.14, citing only small adjustments to projected revenue growth, profit margins and future P/E assumptions that do not materially alter their overall view of the stock. What's in the News No recent company specific news for Mega Lifesciences has been provided in the available sources.ナラティブの更新 • May 24
MEGA: Higher Margin Outlook And Dividend Decision Will Support Future Upside
Analysts have trimmed their price target for Mega Lifesciences slightly to THB 41.14 from THB 41.17, reflecting updated assumptions that now pair a lower revenue growth outlook of 4.12% with a higher projected profit margin of 16.40% and a modestly lower future P/E of 16.67x. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).ナラティブの更新 • May 06
MEGA: Stable Outlook And Upcoming Dividend Decision Will Drive Further Upside
Analysts have kept their fair value estimate for Mega Lifesciences steady at THB41.17 per share, with only minimal model tweaks related to the discount rate, profit margin outlook and future P/E assumptions. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).ナラティブの更新 • Apr 21
MEGA: Higher Growth And Lower Margins Will Likely Keep Shares Fairly Valued
Analysts have lifted their price target on Mega Lifesciences from THB 32 to THB 35, citing updated assumptions around higher revenue growth, a slightly lower discount rate and a revised future P/E multiple, partially offset by a more conservative profit margin outlook. What's in the News Board meeting scheduled for Feb 24, 2026, to consider a dividend payment proposal for the year ended Dec 31, 2025 (company filing).ナラティブの更新 • Apr 06
MEGA: Stable Outlook And Upcoming Dividend Decision Will Support Upside
Analysts have maintained their price target for Mega Lifesciences at THB41.17, citing unchanged assumptions regarding fair value, discount rate, revenue growth, profit margin, and future P/E. What's in the News A board meeting is scheduled for February 24, 2026, to consider a dividend payment proposal for the year ended December 31, 2025 (Key Developments).ナラティブの更新 • Mar 23
MEGA: Higher Fair Value And Upcoming Dividend Decision Will Support Upside
Analysts have lifted their fair value estimate for Mega Lifesciences from THB 38.21 to THB 41.17, citing updated assumptions for long term profit margins and a higher future P/E multiple. What's in the News A board meeting is scheduled for February 24, 2026 for Mega Lifesciences Public Company Limited.
ナラティブの更新 • Mar 09
MEGA: Higher Future P/E Will Support Upgraded Fair Value Outlook
Analysts have lifted their price target for Mega Lifesciences from THB 41.60 to THB 45.00. They highlighted updated assumptions that include slightly lower revenue growth and profit margins, together with a higher future P/E multiple.ナラティブの更新 • Feb 23
MEGA: Updated Discount Rate And Margins Will Support Fair Pricing Ahead
Analysts have raised their price target on Mega Lifesciences to THB 38.21 from THB 34.58, citing updated assumptions related to slightly lower discount rates, adjusted revenue growth, modestly different profit margins and a revised future P/E multiple. Valuation Changes Fair Value: THB 34.58 to THB 38.21, indicating a modest uplift in the assessed share valuation.ナラティブの更新 • Feb 09
MEGA: Fair Outlook Will Balance Softer Margins With Stronger Revenue Expectations
Narrative update on Mega Lifesciences The analyst price target for Mega Lifesciences has been lifted from ฿39.00 to ฿41.60, with analysts linking this change to updated assumptions for slightly lower discount rates, higher forecast revenue growth, a modestly softer profit margin, and a higher future P/E multiple. Valuation Changes Fair Value Estimate: Raised from THB 39.00 to THB 41.60, a small uplift in the assessed equity value.ナラティブの更新 • Jan 25
MEGA: Stable Assumptions And Margins Will Support Fair Pricing Ahead
The analyst price target for Mega Lifesciences remains unchanged at ฿34.58, with analysts citing consistent assumptions for fair value, discount rate, revenue growth, profit margin, and future P/E. Valuation Changes Fair value: Unchanged at THB34.58 per share, with no adjustment to the underlying assumptions.ナラティブの更新 • Jan 10
MEGA: Higher Margin Assumptions Will Likely Leave Shares Overvalued
The analyst fair value estimate for Mega Lifesciences has been adjusted from ฿26.00 to ฿32.00, with analysts pointing to updated assumptions around revenue growth, profit margins and forward P/E to support the higher target. Valuation Changes The fair value estimate has risen from THB 26.00 to THB 32.00 per share, reflecting updated assumptions in the model.ナラティブの更新 • Dec 24
MEGA: Stable Margins And Earnings Outlook Will Support Fair Pricing Ahead
Analysts have reaffirmed their price target on Mega Lifesciences at THB 34.58 per share, citing unchanged assumptions for discount rate, revenue growth, profit margins, and future valuation multiples, which together support a steady outlook for the company’s fair value. Valuation Changes Fair Value: Unchanged at approximately THB 34.58 per share, indicating no revision to the overall equity valuation.ナラティブの更新 • Dec 09
MEGA: Stable Margins And Earnings Outlook Will Support Fair Pricing Ahead
Analysts have maintained their price target on Mega Lifesciences at THB 34.58 per share, reflecting steady assumptions on revenue growth, profit margins, and valuation multiples despite the latest review of fundamentals. Valuation Changes Fair Value: Unchanged at approximately THB 34.58 per share, indicating no revision to the core valuation thesis.ナラティブの更新 • Nov 25
MEGA: Improved Profit Margins And Revenue Estimates Suggest Fair Valuation Ahead
Analysts have raised their price target for Mega Lifesciences from THB 32.14 to THB 34.58. This reflects improved revenue growth forecasts and a slightly stronger profit margin outlook.新しいナラティブ • Jun 01
Expansion In Indonesia And Vietnam Will Fuel Emerging Wellness Markets
Strategic expansion in high-growth markets and local manufacturing reduce operational risks and support sustainable revenue and margin growth.株主還元
| MEGA | TH Pharmaceuticals | TH 市場 | |
|---|---|---|---|
| 7D | 1.4% | 0.6% | 0.2% |
| 1Y | 37.5% | -3.2% | 43.8% |
業界別リターン: MEGA過去 1 年間で-3.2 % の収益を上げたTH Pharmaceuticals業界を上回りました。
リターン対市場: MEGAは、過去 1 年間で43.8 % のリターンを上げたTH市場を下回りました。
価格変動
| MEGA volatility | |
|---|---|
| MEGA Average Weekly Movement | 5.3% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in TH Market | 9.8% |
| 10% least volatile stocks in TH Market | 2.1% |
安定した株価: MEGA 、 TH市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: MEGAの 週次ボラティリティ ( 5% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1982 | n/a | Vivek Dhawan | www.megawecare.com |
メガ・ライフサイエンス社（Mega Lifesciences Public Company Limited）は、その子会社とともに、東南アジアおよびサハラ以南のアフリカにおいて、健康食品、医療用医薬品、一般用医薬品、ハーブ製品、ビタミン剤、日用消費財の製造・販売を行っている。同社は3つのセグメントで事業を展開している：ブランド事業、流通事業、OEM事業である。アレルギー、血液循環・記憶、骨・関節、肝臓・消化器、糖尿病、目・心臓・スキンケア、痛み、睡眠、健康、ハーブ、咳・風邪、ビタミン、プロバイオティクス、医療・スポーツ栄養、子供・男性・女性用ケア用品など、様々な医薬品を提供している。また、抗アレルギー、抗感染症、中枢神経系、循環器系、皮膚科、糖尿病、消化器科、婦人科、腎臓科、腫瘍科、眼科、整形外科、疼痛、呼吸器科、リウマチ科、泌尿器科の処方箋医薬品も提供している。また、第三者が製造した商品を販売するための物流・マーケティングサービス、社会事業、ウェルネスセンターを提供するほか、ソフトウェアの設計・開発、その他のサービス事業にも携わっている。同社は1982年に設立され、タイのバンコクに本社を置いている。メガ・ライフサイエンス社はユニストレッチ社の子会社。
Mega Lifesciences Public Company Limited 基礎のまとめ
| MEGA 基礎統計学 | |
|---|---|
| 時価総額 | ฿31.17b |
| 収益（TTM） | ฿2.07b |
| 売上高(TTM) | ฿14.40b |
15.1x
PER（株価収益率2.2x
P/SレシオMEGA は割高か？
公正価値と評価分析を参照収益と収入
| MEGA 損益計算書（TTM） | |
|---|---|
| 収益 | ฿14.40b |
| 売上原価 | ฿6.85b |
| 売上総利益 | ฿7.55b |
| その他の費用 | ฿5.48b |
| 収益 | ฿2.07b |
直近の収益報告
Mar 31, 2026
次回決算日
Aug 13, 2026
| 一株当たり利益（EPS） | 2.37 |
| グロス・マージン | 52.40% |
| 純利益率 | 14.35% |
| 有利子負債／自己資本比率 | 4.6% |
MEGA の長期的なパフォーマンスは？
過去の実績と比較を見る配当金
4.5%
現在の配当利回り67%
配当性向企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/06/16 08:56 |
| 終値 | 2026/06/16 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Mega Lifesciences Public Company Limited 7 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。15
| アナリスト | 機関 |
|---|---|
| Thanapol Jiratanakij | CGS International |
| Chanpen Sirithanarattanakul | DBS Bank Ltd |
| Nantika Wiangphoem | DBS Bank Ltd |